Medication info
Losartan Plus Tablet

Losartan Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
(Co., Ltd.) Yuhan
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200600123 · Approved 2006.03.22 · Insurance code 642100330

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect is not achieved with monotherapy. 1. Substitution therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be substituted with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Subsequently, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or greater. Since loop diuretics are preferable to thiazide drugs in patients with more severe renal impairment, use in these patients is not recommended. ○ Patients with hepatic impairment Since the initial dose of losartan potassium of 25 mg required for patients with hepatic impairment cannot be administered using this drug, use in these patients is not recommended.
Child dose
○ Children (under 18 years of age) Since there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination product should not be administered to children or adolescents.

Ingredients

Manufacturer
(Co., Ltd.) Yuhan

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used to more effectively manage the blood pressure of hypertensive patients for whom control is difficult with monotherapy alone.

How to take

Adult dose

○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect is not achieved with monotherapy. 1. Substitution therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be substituted with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Subsequently, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or greater. Since loop diuretics are preferable to thiazide drugs in patients with more severe renal impairment, use in these patients is not recommended. ○ Patients with hepatic impairment Since the initial dose of losartan potassium of 25 mg required for patients with hepatic impairment cannot be administered using this drug, use in these patients is not recommended.

Child dose

○ Children (under 18 years of age) Since there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination product should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus, especially if taken during the second and third trimesters of pregnancy. Therefore, if pregnancy is confirmed, it should be discontinued immediately. This medication should not be administered to patients with allergies to it or those with certain kidney diseases, liver diseases, or electrolyte imbalances. Exercise caution when prescribing to patients with a history of hypotension, decreased kidney function, liver dysfunction, gout, hypercalcemia, and similar conditions. During use, blood pressure may drop too low, so if symptoms such as dizziness or fainting occur, consult a physician. This medication may affect serum potassium levels, and potassium supplements or potassium-rich foods should not be taken arbitrarily. Due to the presence of hydrochlorothiazide, electrolyte imbalances, hypotension, or dehydration symptoms may occur, thus regular blood tests and monitoring of symptoms are necessary. This medication may increase the risk of skin cancer when exposed to sunlight, so precautions such as using sunscreen and carefully observing skin conditions while outdoors are advised. Dizziness or drowsiness may occur during driving or operating machinery, so caution is required. Because this medication may interact with other drugs, inform your doctor or pharmacist if you are taking any other medications, particularly diuretics, potassium-sparing agents, or nonsteroidal anti-inflammatory drugs. This medication is not indicated for use in children or adolescents, and older adults should use it cautiously as adverse effects may occur more frequently. Women who are pregnant or breastfeeding should consult with a physician prior to use, and it is advised to avoid use while breastfeeding. In case of suspected overdose, which may lead to hypotension or cardiac rhythm anomalies, visit a medical institution immediately.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • swelling
  • palpitations
  • back pain
  • dizziness
Show 128 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin detachment phenomenon
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • dental pain
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neuroexcitability
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • shortness of breath
  • nasal bleeding
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus dysfunction
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • itching
  • sweating
  • hives
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • frequent urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • hyperuricemia
  • muscle spasms
  • nervousness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • mucocutaneous syndrome
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • yellowing of the skin
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylaxis
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a dark, tightly sealed container. A cool storage temperature between 15 to 30 degrees Celsius is suitable. Proper storage will maintain the medication's effectiveness and safety.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.